Tesamorelin Peptide: Uses, Benefits, and Effects

(Growth hormone releasing hormone (GHRH))

How it works:
Tesamorelin is a growth hormone releasing hormone (GHRH) analog that increases IGF-1 levels in both men and women. It binds to and stimulates GHRH receptors with similar potency as endogenous GHRH. Other benefits include nootropic effects and reducing triglycerides. Tesamorelin has subsequently been shown to decrease carotid intima-medial thickness (cIMT), visceral adipose tissue (VAT), and c-reactive protein (CRP).

Key Benefits:
Clinical trials have shown that Tesamorelin significantly reduces abdominal fat. Additionally, it can improve cognitive function for seniors and patients with an increased risk of Alzheimer’s disease, due to mild cognitive impairment.

Content & Potency:
Injectable
2.5mg Vial: Reconstitute 5ml with BWFI (.5mg/ml – 5ml)
5mg Vial: Reconstitute 5ml with BWFI (1mg/ml – 5ml)
.20ml daily or .10ml twice a day subcutaneously

Frequently Asked Questions

What is tesamorelin peptide used for?

Tesamorelin is a growth hormone releasing hormone (GHRH) analog that helps stimulate your body’s natural growth hormone pathway and increase IGF-1 levels. It is commonly used to target visceral abdominal fat and may also support metabolic and cognitive health in appropriate patients.

Can tesamorelin help reduce belly fat?

Yes, clinical research has shown tesamorelin can significantly reduce visceral adipose tissue, the deeper abdominal fat around the organs. It is not a general weight-loss shot, but it may be useful for patients whose main concern is stubborn central abdominal fat.

What other benefits can tesamorelin have besides fat reduction?

Tesamorelin may help lower triglycerides and inflammatory markers such as CRP, and it has been associated with reduced carotid intima-media thickness, a marker related to vascular health. It may also offer nootropic support, with potential cognitive benefits for some older adults or patients with mild cognitive impairment.

How is tesamorelin taken?

Tesamorelin is typically given as a subcutaneous injection after the vial is reconstituted with bacteriostatic water. A clinician should determine the proper concentration, dose, and schedule, which may be once daily or split into two smaller daily injections depending on the treatment plan.